IMCD opens Japan office

By Gareth Macdonald

- Last updated on GMT

iStock/tadamichi
iStock/tadamichi

Related tags Ho chi minh

IMCD has opened a sales office in Japan citing growing demand for pharmaceutical fine chemicals and food ingredients.

Operations at the office in Tokyo will be oversee by newly appointed managing director Shunsaku Kubo, who joins the Dutch distributor after a 20-year career in the chemical manufacturing industry.

An IMCD spokeswoman told us that “our new office in Japan will follow IMCD's general business model. In that sense, we do expect Pharma to be one of the markets where we will be active in Japan.”

She also suggested IMCD may expand the office, explaining that: “For the time being it is a sales office, but we will adapt our activities to the demands of the market. One of Mr. Kubo's first tasks will be to establish relations with customer and suppliers in the markets​.”

The opening of the Tokyo office follows six months after IMCD’s last investment in Asia.

In September the firm opened a sales operation in Ho Chi Minh City, Vietnam describing the move as “the latest of a succession of steps that IMCD has taken to build up presence in Asia Pacific​.”  

Financials

According to financial results released earlier this month, the EuroNext Amsterdam listed distributor’s revenue and operating profit for 2015 were €1.52bn ($1.72bn) and €128m, up 13% and 17% year-on-year, respectively.

Revenue generated in Europe was €968m, up just 1% on 2014. This contrasts with revenue generated in Asia, which increased 9% to €310m.

Global expansion

In addition to building in Asia, IMCD has also increased its presence in other markets. In June 2015 IMCD bought an 80% stake in MF Cachat – a specialty chemical distributor. In January this year it opened a sales office in New Jersey.

Of more relevance to the drug industry was its acquisition of Brazil-based active pharmaceutical ingredient (API) distributor Selectchemie.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars